Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Development of a vaccine against herpes simplex virus 2 infection

Jan-Åke Liljeqvist

Contact Information | List of Publications

Herpes simplex virus type 2 (HSV-2) gives a chronic and life-long infection with more than 400 million individuals infected world-wide. Besides recurrent painful genital lesions a major global problem is that HSV-2 infection significantly facilitates HIV transmission. We develop a vaccine against HSV-2 infection using the viral glycoprotein G (gG-2). Based on the observations that cross-reactive immune responses after an HSV-1 infection do not protect from HSV-2 infection we suggest that a vaccine should be based on an HSV-2 type specific component. gG-2 is the only highly immunogenic viral envelope protein which elicits type specific immune responses. We have shown that gG-2 confers protection in a vaccination mouse model and will now continue the pre-clinical development of a vaccine into phase I/II clinical trials.

Group Members

Jan-Åke Liljeqvist MD, ass. prof. group leader, and senior physician in virology at the Sahlgrenska University Hospital.
Staffan Görander, MD, PhD,
Karin Önnheim, PhD, post.doc position
Carolina Gustafsson, technician

Sidansvarig: Dan Baeckström|Sidan uppdaterades: 2016-10-24
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?